Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $61

Benzinga · 1d ago
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $68 to $61.